PMID- 37038217
OWN - NLM
STAT- MEDLINE
DCOM- 20230627
LR  - 20230627
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 202
IP  - 1
DP  - 2023 Jul
TI  - Baseline circulating tumour DNA and total metabolic tumour volume as early 
      outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient 
      cohort.
PG  - 54-64
LID - 10.1111/bjh.18809 [doi]
AB  - Approximately 20%-50% of patients with large B-cell lymphoma (LBCL) experience 
      poor outcomes. We aimed to evaluate the combined prognostic value of circulating 
      tumour DNA (ctDNA) and total metabolic tumour volume (TMTV) in LBCL. This 
      observational single-centre study included 112 newly diagnosed LBCL patients, 
      receiving R-CHOP/R-CHOP-like chemotherapies. CtDNA load was calculated following 
      next-generation sequencing of cell-free DNA (cfDNA) using a targeted 40-gene 
      lymphopanel. TMTV was measured using a fully automated artificial 
      intelligence-based method for lymphoma lesion segmentation. CtDNA was detected in 
      cfDNA samples from 95 patients with a median concentration of 3.15 log haploid 
      genome equivalents per mL. TMTV measurements were available for 102 patients. The 
      median TMTV was 501 mL. High ctDNA load (>3.57 log hGE/mL) or high TMTV (>200 mL) 
      were associated with shorter 1-year PFS (44% vs. 83%, p < 0.001 and 64% vs. 97%, 
      p = 0.002, respectively). When combined, three prognostic groups were identified. 
      The shortest PFS was observed when both TMTV and ctDNA load were high 
      (p < 0.001). Even with a short follow up, combining ctDNA load with TMTV improved 
      the risk stratification of patients with aggressive LBCL. In the near future, 
      very high-risk patients could benefit from CAR T-cell therapy or bispecific 
      antibodies as first-line treatments.
CI  - (c) 2023 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Le Goff, Enora
AU  - Le Goff E
AUID- ORCID: 0000-0003-1724-3909
AD  - Lymphoid Malignancies Unit, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
FAU - Blanc-Durand, Paul
AU  - Blanc-Durand P
AD  - Nuclear Medicine Department, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
FAU - Roulin, Louise
AU  - Roulin L
AD  - Lymphoid Malignancies Unit, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
FAU - Lafont, Charlotte
AU  - Lafont C
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
AD  - Public Health Department, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
FAU - Loyaux, Romain
AU  - Loyaux R
AD  - Hematobiology and Immunobiology Department, Assistance Publique des Hopitaux de 
      Paris, HU Henri Mondor, Creteil, France.
FAU - MBoumbae, Diana-Laure
AU  - MBoumbae DL
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
AD  - Hematobiology and Immunobiology Department, Assistance Publique des Hopitaux de 
      Paris, HU Henri Mondor, Creteil, France.
FAU - Benmaad, Ichrafe
AU  - Benmaad I
AD  - Hematobiology and Immunobiology Department, Assistance Publique des Hopitaux de 
      Paris, HU Henri Mondor, Creteil, France.
FAU - Claudel, Alexis
AU  - Claudel A
AD  - Hematobiology and Immunobiology Department, Assistance Publique des Hopitaux de 
      Paris, HU Henri Mondor, Creteil, France.
FAU - Poullot, Elsa
AU  - Poullot E
AD  - Pathology Department, Assistance Publique des Hopitaux de Paris, HU Henri Mondor, 
      Creteil, France.
FAU - Robe, Cyrielle
AU  - Robe C
AD  - Pathology Department, Assistance Publique des Hopitaux de Paris, HU Henri Mondor, 
      Creteil, France.
FAU - Gricourt, Guillaume
AU  - Gricourt G
AD  - Bioinformatics Department, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
FAU - Aissat, Abdelrazak
AU  - Aissat A
AD  - Bioinformatics Department, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
FAU - Copie-Bergman, Christiane
AU  - Copie-Bergman C
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
AD  - Pathology Department, Assistance Publique des Hopitaux de Paris, HU Henri Mondor, 
      Creteil, France.
FAU - Lemonnier, Francois
AU  - Lemonnier F
AD  - Lymphoid Malignancies Unit, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
FAU - Gaulard, Philippe
AU  - Gaulard P
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
AD  - Pathology Department, Assistance Publique des Hopitaux de Paris, HU Henri Mondor, 
      Creteil, France.
FAU - Itti, Emmanuel
AU  - Itti E
AD  - Nuclear Medicine Department, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
FAU - Haioun, Corinne
AU  - Haioun C
AD  - Lymphoid Malignancies Unit, Assistance Publique des Hopitaux de Paris, HU Henri 
      Mondor, Creteil, France.
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
FAU - Delfau-Larue, Marie-Helene
AU  - Delfau-Larue MH
AUID- ORCID: 0000-0002-8010-2343
AD  - Paris-Est Creteil University, INSERM, IMRB, F-94010, Creteil, France.
AD  - Hematobiology and Immunobiology Department, Assistance Publique des Hopitaux de 
      Paris, HU Henri Mondor, Creteil, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20230410
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Circulating Tumor DNA)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Humans
MH  - *Circulating Tumor DNA/genetics
MH  - Tumor Burden
MH  - Artificial Intelligence
MH  - Prognosis
MH  - *Lymphoma, Large B-Cell, Diffuse/genetics/therapy/diagnosis
MH  - Fluorodeoxyglucose F18/therapeutic use
MH  - Positron Emission Tomography Computed Tomography
MH  - Retrospective Studies
OTO - NOTNLM
OT  - circulating tumour DNA
OT  - neoplasm staging
OT  - non-Hodgkin lymphoma
OT  - positron emission tomography computed tomography
OT  - prognosis
EDAT- 2023/04/11 06:00
MHDA- 2023/06/27 06:42
CRDT- 2023/04/10 23:49
PHST- 2023/03/28 00:00 [revised]
PHST- 2023/01/16 00:00 [received]
PHST- 2023/03/31 00:00 [accepted]
PHST- 2023/06/27 06:42 [medline]
PHST- 2023/04/11 06:00 [pubmed]
PHST- 2023/04/10 23:49 [entrez]
AID - 10.1111/bjh.18809 [doi]
PST - ppublish
SO  - Br J Haematol. 2023 Jul;202(1):54-64. doi: 10.1111/bjh.18809. Epub 2023 Apr 10.